Pacira Company profile
About Pacira Biosciences Inc
Pacira BioSciences, Inc. is the holding company of Pacira Pharmaceuticals, Inc. The Company is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain. Its iovera is a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Pacira Biosciences Inc revenues increased 26% to $541.5M. Net income decreased 71% to $42M. Revenues reflect EXPAREL segment increase of 21% to $506.5M, iovera segment increase of 83% to $16.2M. Net income was offset by Amortization of acquired intangible increase of 72% to $13.6M (expense), Other, net decrease from $2.9M (income) to $2.7M (expense).
Equity composition
Common Stock $0.001 Par, 02/11, 120 auth., 17,232,875 issd. Insiders own approx. 9.29%.
Latest shares articles
Ratings and Reviews
Ratings and Reviews
